Mark Cuban (@mcuban) does a great job explaining how middlemen pharmacy benefit managers (PBMs) drive up the cost of prescription drugs for Americans, thus setting up the need for Congress to pass reforms Cuban: The US has the highest drug prices in the world "because we are the only country that uses PBMs"

Congratulations to the class of 2025! 🥳🎊🎂🔥 Proud of your accomplishments and hard work! Congratulations to all the mentors, faculty and family that made this happen. Couldn't have done it without your support! @AllaqabanSuhail @PatrycjaGalazka @fuadfehmi

The KETO-CTA Study: Peeling Back A Layer 🥓🫀 It's been a wild 2-weeks. We've just been told this wasn't "the paper", despite 10 days of promoting and defending it?! In this video, I run through events, comments, and criticisms offered so far. Who knows what's next... #LMHR

When it rains, it pours - More OBI data. Across 3 phase 3 trials, BROADWAY (obi), BROOKLYN (obi) & TANDEM (obi ezetimibe), obicetrapib, an oral CETP inhibitor, effectively reduced not only LDL-C, but also Lp(a), especially in those with moderately elevated Lp(a) levels. In patients with baseline Lp(a) levels ≥50 nmol/L < 150 nmol/L, and with all on high-intensity statins) obicetrapib reduced Lp(a) by 44.8% and in absolute terms by 37.4 nmol/L @nationallipid @society_eas @ASPCardio @escardio @atherosociety #obicetrapib

SCAI wants lead-free cath labs and a better work-life balance for cardiologists ⁦@Pooh_Velagapudi⁩ ⁦@adityadoc1⁩ ⁦@GiorgioMedranda⁩ ⁦@mirvatalasnag⁩ ⁦@CardioBusiness⁩ ⁦@SCAI⁩⁩ ⁦@djc795⁩ ⁦@AnkurKalraMD⁩ cardiovascularbusiness.com/t…

Celebrating 5K TAVR at #AuroraStLukes - largest program in Wisconsin! Congratulations to the wonderful team and so many that have contributed throughout the years! 🎊🥳🔥💪🙏

Learn about the unique role of Lp(a) as a genetic determinant for #ASCVD risk & the importance of testing for Lp(a) levels to better understand your patients’ cardiovascular health w/ ACC's online course. ⬇️ More: bit.ly/3WmPipH #LpaAwarenessDay #KnowLpa #ACCEd

Download SCAI’s latest ebook today on #CardiogenicShock and #MechanicalCirculatorySupport. The ebook covers the essentials, including introductory concepts to device selection and future trends in the field. Learn practical tips to enhance patient outcomes. 💡Section 1: Intro to Cardiogenic Shock and Therapies 💡Section 2: MCS Basics 💡Section 3: Device Review 💡Section 4: Device Selection by Clinical Need 💡Section 5: Future Innovations 🔗scaipro.scai.org/URL/MCSeBoo… #SCAIMCSebook @AdhirShroff @agtruesdell @duanepinto

Transcatheter Cardiovascular Therapeutics Conference Washington, DC #TCT2024

Among patients with asymptomatic severe aortic stenosis, early TAVR was superior to clinical surveillance in reducing the incidence of death, stroke, or unplanned hospitalization for cardiovascular causes. Full EARLY TAVR trial results: nej.md/4hjJZRc #TCT2024

📢 SCAI releases 🆕 eBook on ‘Short-Term MCS for Cardiogenic Shock’ 💡#CardiogenicShock Fundamentals 💡Basics of #MCS 💡In-Depth Device Reviews 💡Device Selection & Combinations 💡Future Innovations 📚Read now: ow.ly/9VbB50TJUl4 @AdhirShroff @agtruesdell @duanepinto

For all cardiology fellows — this is a great book that is free to learn about MCS for cardiogenic shock! @AdhirShroff @CVOMed @SandeepNathanMD @Pooh_Velagapudi @Allison_Dupont @DrJayMohan @DrAnthonyTeta @JasonGKaplanMD

2/2 👍Links to all 3 e-Books right here👉: #1 🔗 scaipro.scai.org/URL/MCS-EBo…, #2 🔗 scaipro.scai.org/URL/Vascula…, and #3 🔗 sccm.org/Education-Center/On…⚡️🫀💥…

1/2 @SCAI Mechanical Circulatory Support e-Book (🔗 scaipro.scai.org/URL/MCS-EBo…): an awesome brand new addition to the “trilogy” (@SCAI Vascular Management and @SCCM Cardiac ICU e-Books): all 3 Free and Online (all 3 links in 2nd Tweet below👇)💥🫀⚡️…

I’m hearing so many people cite conflict of interest as the reason physicians shouldn’t own hospitals. This also happens to be the main strategy the American Hospital Association used to lobby Congress to ban POHs in the Affordable Care Act, paving the way for the consolidated corporate nightmare we enjoy today. The conflict of interest argument is absurd in a for profit healthcare system. Hospitals force their employed physicians to refer to other specialists within their own hospital system. Physicians recommend surgery then do the surgery themselves collecting both a clinic fee and a surgery fee. Optum forces patients to see their doctors, use their pharmacies, and be admitted to their own hospitals. If there is profit to be made in patient care, there will be a conflict of interest among the entities/people collecting that profit. The closest thing to a conflict of interest free system is one that is devoid of profit. Call me cynical, but that will not happen in the US. So we can wring our hands about the potential corruption and malfeasance evil greedy doctors will inflict upon our great country if physicians owned hospitals, while ignoring the actual corruption and malfeasance already displayed by hospital corporations. We can ignore data that shows POHs as a whole (~250 in the US, holdovers from pre-ACA times) have better outcomes at lower costs. Or we can introduce some actual competition in the healthcare marketplace to give patients a chance for better care from people who actually got into this business to treat patients, care that is not dictated by a private equity company or insurance company. Just give physicians a chance to show that we can do a better job. That’s all we’re asking. If we suck at it, we won’t get very far, right? Isn’t that what the free market is for? Repeal the ban on physician owned hospital.

High lipoprotein(a) [(Lp(a)] is a genetically determined, important risk factor for cardiovascular disease that should be (but isn't) routinely measured (at least once). There are 5 drugs that look highly effective for markedly lowering levels in clinical trials. This new @TheLancet review is excellent! thelancet.com/journals/lance…

Surreal and somber flight into🗽NYC 🍎 on September 11th 🙏🏼 @nycgov @LGAairport @EndovascularNy #september11th

Role of apoB in Clinical Management infographic. Via @nationallipid @LipidJournal

The Acropolis of Athens ✨

Role of apolipoprotein B in the clinical management of cardiovascular risk in adults: An Expert Clinical Consensus from the National Lipid Association - Journal of Clinical Lipidology @nationallipid lipidjournal.com/article/S19…